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SUMMARY
Background and purpose—Ziconotide is a peptide that blocks N-type calcium channels and
is anti-hyperalgesic after intrathecal delivery. We here characterize the spinal kinetics of
intrathecal bolus and infused ziconotide in dog.
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Experimental approach—Male beagle dogs (N = 5) were prepared with chronic intrathecal
(IT) lumbar injection and cerebrospinal fluid (LCSF) sampling catheters connected to vest-
mounted pumps. Each dog received: i) IT bolus ziconotide (10 µg + 1 µCi 3H-inulin), ii) IT
infusion for 48 hr of ziconotide (1 µg/100 µL/hr), iii) IT infusion for 48 hr of ziconotide (5 µg/100
µL/hr), and iv) intravenous injection of ziconotide (0.1 mg/kg). After IT bolus, LCSF ziconotide
and inulin showed an initial peak and biphasic (distribtution/elimination) clearance (ziconotide
T1/2 α / ß = 0.14 and 1.77 hr, and inulin T1/2 α / ß = 0.16 and 3.88 hr, respectively). The LCSF:
plasma ziconotide concentration ratio was 20,000: 1 at 30 min, and 30: 1 at 8 hr. IT infusion of 1
and then 5 µg/hr resulted in LCSF concentrations that peaked by 8 hr and remained stable at 343
and 1380 ng/mL, respectively, to the end of the 48-hr infusions. Terminal elimination T1/2 after
termination of continuous infusion was 2.47 hr. Ziconotide LCSF: cisternal CSF: plasma
concentration ratios after infusion of 1 µg/hr and 5 µg/hr were 1: 0.017: 0.001 and 1: 0.015: 0.003,
respectively. IT infusion of ziconotide at 1 µg/hr inhibited thermal skin twitch by 24 hr, and
produced modest trembling, ataxia, and decreased arousal. Effects continued through the 48-hr
infusion period, increased in magnitude during the subsequent 5 µg/hr infusion periods, and
disappeared after drug clearance.
Conclusions and Implications—After intrathecal bolus or infusion, ziconotide displays linear
kinetics that are consistent with a hydrophilic molecule of approximately 2500 Da that is cleared
slightly more rapidly than inulin from the LCSF. Behavioral effects were dose dependent and
reversible.
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INTRODUCTION
Ziconotide is the synthetic equivalent of a 25 amino acid peptide originally identified in the
venom of the cone snail, Conus magus. (1,2) Early work emphasized that ziconotide and
related peptides are highly selective antagonists of the N-type voltage-sensitive calcium
channel. (3,4,5) N type channels are considered to be important for terminal transmitter
release and we have shown that intrathecal delivery of ziconotide will indeed block release
of substance P from small nociceptive primary afferents. (6) Subsequent work revealed that
block of this channel would exert a potent anti- hyperalgesic and anti-allodynic effect in
models of tissue and nerve injury when given intrathecally in the rat. (7,8,9,10)
Autoradiographic binding studies showed that the densest localization of the ziconotide
binding site in the spinal cord is in the dorsal spinal lamina (substantia gelatinosa) (11), a
region known to be pivotal in processing nociceptive information. (12)
Studies in humans have also shown that intrathecal bolus injection or continuous infusion of
ziconotide is efficacious in a variety of acute and chronic pain states (13, 14, 15, 16, 17,18)
and in ameliorating spasticity secondary to spinal injury. (19) Initial studies reported
significant adverse effects with dose incrementation, (15, 20) which may have reflected an
incomplete appreciation of the kinetics of redistribution of the intrathecally delivered drug.
To address this issue, we undertook pharmacokinetic studies to characterize the spinal
kinetics of ziconotide after bolus intrathecal injection, during and after continuous
intrathecal infusion, and after intravenous delivery in a well-defined beagle dog model that
uses chronically placed lumbar intrathecal catheters. (21,22,23,24)
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Studies were carried out under protocols approved by the Institutional Animal Care and Use
Committee of the University of California, San Diego.
Drug/Injectate
Ziconotide and saline diluent were furnished by the Neurex Corporation (now Elan
Corporation, South San Francisco, CA). Ziconotide for injection was prepared by aseptic
dilution with saline diluent. Solutions were not filtered. Drug dilutions and reconstitutions
were made just prior to dosing.
Animals
Male beagle dogs (N = 5) were obtained from Harlan Sprague Dawley, Inc. (Ridgeland
Farms, Mt. Horeb, WI). These dogs were between 9 and 18 months old and weighed
between 12 and 16.5 kg at the start of the study. All animals had free access to dry dog food,
with the exception of the nights prior to scheduled clinical pathology, surgery, and sedation.
Tap water was available ad libitum. Animals were individually housed in 4- foot by 7-foot
inside runs.
Surgical preparation
After an initial acclimation (3–7 days), dogs underwent surgical implantation of intrathecal
injection and sampling catheters to be used for repeated intrathecal dosing and sampling.
Catheter placement was performed following strict aseptic precautions. All catheters were
fabricated and packaged on site and locally sterilized by e-beam irradiation. Surgery was
performed approximately 72 to 96 hr (study day −4 and −3) prior to initiation of dosing.
Animals received atropine (0.04 mg/kg, IM) prior to sedation with xylazine (Rompun; 1.5
mg/kg, IM). Tribrissen (15–20 mg/kg, oral, twice daily for 5 days) was given as a
prophylactic antibiotic. Anesthesia was mask-induced and the animals were then intubated
and maintained under spontaneous ventilation with 1–2% Halothane and 60% N2O and
40%O2. Animals were continuously monitored for oxygen saturation, inspired and end-tidal
gas, expired CO2, N2O, O2 and heart and respiratory rates. Surgical areas were shaved and
prepped with chlorhexadine scrub and solution. Dexamethasone sodium phosphate (0.25
mg/kg, IM) was given immediately following completion of intrathecal catheter placements.
Using sterile technique, a skin incision was made on the lower back of the neck. The
cisterna magna was then exposed by combined blunt and sharp dissection. The dura was
then exposed and two small incisions (0.5 mm) were made and the prepared catheters were
then individually inserted and passed caudally. The catheters were fabricated of
polyethylene PE10 (0.4 mm O.D.), for the infusion catheter, and PE50 (0.97 mm O.D.), for
the sampling catheter (Intramedic©, Becton Dickinson). The PE10 catheter was passed
approximately 40 cm to the L2–3 level. The PE50 catheter was passed through an adjacent
incision approximately 38 cm. The internal segments of the catheters were then connected to
50 cm PE100 external segments and tunneled subcutaneously and caudally to exit on the
upper left and right back at the level of the scapula. Confirmation of the appropriate
placement of the catheters in the intrathecal space was based on the free outflow of CSF.
The incision was closed in layers using 3–0 Vicryl®. With closure of the incision, anesthesia
gases were turned off and the animals allowed to recover under observation. Butorphanol
tartrate (Torbugesic; 0.04 mg/kg, IM) was administered to relieve post-operative discomfort.
A nylon vest (Alice King Chatham Medical Arts, Hawthorne, CA) was placed on each dog
following surgical recovery and a Panomat C-10 infusion pump (Disetronics Medical
Systems, Plymouth, MN) was placed in the left vest pocket and connected to the PE50
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sampling catheter. The pump was set to deliver approximately 100 µL/hr of 0.9% w/v
Sodium Chloride for Injection, USP, to maintain sampling catheter patency.
Study Design
Each dog received: i) one intrathecal bolus injection of ziconotide (10 µg in 1 mL), ii)
chronic intrathecal infusion over two sequential 48-hr intervals of two concentrations of
ziconotide (1 µg/hr IT followed by 5 µg/hr IT, respectively, at 100 µl/hr), and iii) lastly, an
intravenous bolus injection of ziconotide (0.1 mg/kg). All intrathecal bolus injections were
spiked with 1 µCi 3H-inulin and followed by 0.3 mL 0.9% (w/v) Sodium Chloride for
Injection, USP, as catheter flush.
Behavioral Observations
Animals were observed for arousal, motor function, and motor strength on a 4-point scale
(22). Morbidity/mortality and clinical observations were noted twice daily (morning and late
afternoon). On dosing days, the morning clinical observations were conducted prior to
dosing. Appetite, presence of stool and urine, general behavior, overt signs of toxicity, and
body temperatures were recorded daily.
Heart rate and blood pressures were measured using a tail cuff manometer (Dinamap 8100,
Critikon). Respiratory rates were measured by visualization of chest expansion and
contraction. These measurements were made periodically before and after each injection and
during infusion intervals.
The thermally evoked nociceptive skin twitch response was measured using a probe with
approximately 1 cm surface area maintained at approximately 62.5°C ± 0.5°C with a
feedback. (24) The probe was applied to shaven lumbar areas of the back. This stimulus
results in a brisk contraction of the local, underlying musculature within 1–3 sec of the
probe placement. Upon appearance of this response, the probe was removed and the latency
recorded. Failure to respond within 6 sec was cause to remove the probe and assign that
value (6 sec) as the latency.
Kinetics
LCSF (approximately 0.3 mL) and blood samples (approximately 1 mL) were collected
from each animal before and during dosing intervals. Blood samples were collected on wet
ice and prepared as plasma in lavender EDTA-coated test tubes. Cisternal CSF samples
(approximately 0.3 mL) were obtained by percutaneous puncture (1.5 inch 22 ga spinal
needle) in the lightly anesthetized dog three times: i) just prior to the initiation of 1 µg/hr
ziconotide chronic intrathecal infusion, ii) 48 hr later, just prior to the dose change to 5 µg/hr
ziconotide infusion, and iii) 48 hr later just prior to termination of chronic intrathecal
infusion. All samples were collected onto dry ice and stored frozen at approximately −20°C
± 10°C until assay.
Ziconotide assays were performed using a validated radioimmunoassay (RIA) using 125I-
ziconotide and a ziconotide-specific antibody. In this assay, the 125I-ziconotide-antibody
complexes are separated from unbound 125I-ziconotide by adsorption to charcoal and the
radioactivity in the complexes measured by gamma counting. Ziconotide in a sample
inhibits the binding of 125I-ziconotide to the antibody and the amount of ziconotide in the
sample is calculated by comparison to a standard curve. The lower limit of quantification of
the RIA for dog CSF and plasma is 0.07 ng/ml of ziconotide. Standard curves and blanks
were established using dog cisternal cerebrospinal fluid and dog plasma. Additional details
and characteristics of this assay are presented elsewhere. (25)
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After completion of the final dosing interval and sample collection, animals were deeply
anesthetized with sodium pentobarbital and intubated, with ventilation being manually
maintained. The chest was then opened, the aorta catheterized, and the blood cleared by
perfusion at 80 to 160 mmHg of pressure, with approximately 4 L of 0.9% saline. The spinal
column was then exposed by laminectomy. Methylene blue dye was injected through both
intrathecal catheters to establish their patency and to visualize their position relative to each
other.
Statistical and Kinetic Analyses
Behavioral scores (arousal, muscle tone, and coordination), physiological parameters (blood
pressures and heart and respiratory rates) and skin twitch response latencies are presented as
mean and standard error of the mean (S.E.M.). The pharmacokinetic analyses were done
using PK Solutions software (PK Solutions, Version 2.0 SUMMIT Research Services 1374
Hillcrest Drive, Ashland, OH 44805, Copyright 1999). Area under the concentration-time
curves (AUC) for plasma and CSF were estimated by the trapezoidal rule up to the last
observed concentration (Clast). For concentrations below the limit of detection, a value of
one-half the detection limit was used. If the last concentration was detectable, then AUC0-∞
was estimated as AUC up to the last observed concentration (AUC0-τ) + Clast/λz, where λz
is the elimination rate constant estimated by linear regression of the terminal portion of the
concentration-time curve. Clearance (CL) was calculated as F*D/AUC, where
F=bioavailability and D = dose administered. Apparent volume of distribution (Vz) was
estimated by CL*λz, and relates the amount of drug in the body to the sampled matrix
concentration during the terminal phase. Volume of distribution at steady-state (Vss) was
estimated as (D)(AUMC0-∞)/(AUC0-∞), where AUMC is the total area under the first
moment curve, and relates the amount of drug in the body to the sampled matrix
concentration at steady-state. The analysis used curve stripping methods, where drug
concentration data in blood or CSF are resolved into a series of rate constant terms
corresponding to the absorption, distribution, and elimination phases. Half-lives are then
estimated as 0.693/k, where k is the corresponding rate constant for that phase. Two rate
constants were estimated, and correspond to either: distribution and elimination (when the
concentrations are being measured in the matrix where the dose was administered), or
absorption/distribution and elimination (when the concentrations are being measured in a
different compartment from where the dose was administered). The following parameters
were determined:
1) Bolus intrathecal injection: CSF and plasma levels of ziconotide and 3H-inulin
versus time. For LCSF and plasma: T½ of distribution (T½-α) (LCSF) or
absorption/distribution (plasma), T½ of elimination (T½-β), peak concentration
(Cmax), time to peak concentration (Tmax), area under the concentration-time
curve (AUC0-∞), ratio of LCSF ziconotide (µg/mL) to LCSF inulin
2) (DPM) versus time, and ratio of LCSF ziconotide to plasma ziconotide versus
time. A general (rough) estimate of the absolute bioavailability of ziconotide in
plasma (Fplasma), following bolus IT ziconotide administration, can be
determined using the following equation: ,
where CLIV = plasma CL after an IV dose and CLIT = plasma CL/F after the
intrathecal dose.
2) Continuous intrathecal infusion: CSF and plasma levels of
ziconotide versus time to steady state, steady state concentration
(mean of values measured from time of steady state to end of
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infusion), clearance at steady-state, calculated as intrathecal infusion
rate divided by steady-state concentration, ratio of LCSF ziconotide
to plasma ziconotide versus time, and ratio of LCSF to cisternal CSF
to plasma ziconotide at steady state.
3) Termination of continuous intrathecal infusion:CSF and plasma
levels of ziconotide and 3H-inulin versus time. For LCSF and
plasma: T½ of elimination (T½-β), and ratio of LCSF ziconotide to
plasma ziconotide versus time.
4) Bolus intravenous injection: Peak concentration (Cmax) for LCSF and plasma
ziconotide, time to peak concentration (Tmax), and area under the time-
concentration curve (AUC0-∞). Similar to section 1 above, a general (rough)
estimate of the absolute bioavailability of ziconotide in CSF (FCSF), following
bolus IV ziconotide administration, can be determined using the following
equation: , where CLIV = CSF CL/F after IV
administration and CLIT = CSF CL after intrathecal administration.
RESULTS
All animals survived surgery without mishap and completed the intended protocol. At the
time of sacrifice, all catheters were patent and were located in the targeted lumbar spinal
region with the tip of the sampling catheter located approximately 2 cm rostral to the tip of
the dosing catheter. Mean body weight at the time of these studies was 14.5 ± 0.9 kg. Plasma
samples were obtained for assay for all animals. Lumbar CSF samples were reliably
obtained from 4 of the 5 animals. These samples were employed for the subsequent analysis
of ziconotide concentrations.
Kinetics
Intrathecal Bolus—Intrathecal (IT) bolus delivery of ziconotide (10 µg) resulted in peak
concentrations in LCSF by the first sampling interval (i.e., 3 min) and with a biphasic
(distribution/elimination) clearance (T1/2 α / ß = 0.14 and 1.68 hr, respectively). (See Figure
1 and Table 1.) Examination of ziconotide concentrations in plasma revealed a peak at 20
min. At this time, the CSF : plasma ratio was approximately 20,000: 1 and declined over the
ensuing 8 hr to approximately 30: 1. Based on median plasma CLIV dose and plasma
CLIT dose values, Fplasma = 53.5%. Note: this general estimate assumes linear PK, which
may not apply over the wide plasma ziconotide concentration range evaluated.
3H-Inulin, injected intrathecally concurrently with ziconotide, displayed a clearance profile
similar to that of ziconotide with a similar T1/2α but a longer T1/2 ß (T1/2 α and ß = 0.16 and
3..04 hr, respectively).The slower inulin clearance is confirmed by inspection of the ratio of
ziconotide: inulin concentrations determined concurrently in LCSF of each sample over
time. This ratio fell from approximately 0.006 ng/DPM (essentially equivalent to that which
was injected) to approximately 0.0005 by 8 hr. (See Figure 1)
Intravenous Bolus—IV bolus delivery of 0.1mg/kg ziconotide resulted in an immediate
peak plasma concentration (approximately 900 ng/mL), a terminal elimination half-live of
1.3 hrs. (See Figure 2 and Table 2.) The LCSF Cmax after IV delivery was 21 ng/mL
observed at 45 min. At plasma Cmax, the plasma: LCSF ratio was 850: 1, declining to 3: 1 at
45 min, and to 1: 1 at 8 hr. Based on median CSF CLIV dose and CSF CLIT dose values, FCSF
= 0.013%. Note: this general estimate also assumes linear PK, which may or may not apply
over the wide CSF ziconotide concentration range evaluated.
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Intrathecal Infusion—After the initiation of the 1 µg/hr intrathecal infusion, ziconotide
concentration in LCSF peaked by 8 hr and remained essentially stable through the 8–48 hr
infusion (median CSF concentration for 8–48 hr = 286 ng/mL). (See Table 3.) Plasma levels
of ziconotide peaked by 8 hr and remained essentially stable through the remaining 8–48 hr
infusion (median plasma concentration for 8–48 hr was at the limits of detection for 3
animals)
After initiating a 5-fold increase in infusion dose (5 µg/hr), time to peak CSF concentrations
was also approximately 8 hr and remained essentially stable through the 8–48 hr infusion
(median CSF concentration for 8–48 hr = 1620 ng/mL). (See Table 3.) With 5 µg/hr, a
similar concentration- time profile was observed in plasma, with the 8–48 hr group mean
concentration being 1.1 ng/mL. (See Figure 3 and Table 3.) The ratio of ziconotide in LCSF
versus plasma was approximately 2400: 1 at 8 hr, 1200: 1 at 24 hr and 600: 1 at 48 hr.
Following termination of the 5 µg/hr infusion, LCSF ziconotide concentrations fell, showing
a monophasic clearance with a mean terminal elimination T1/2 of 2.35 hr (See Figure 3/
Table 3.)
Cisternal CSF ziconotide concentrations, prior to initiating infusion of 1 µg/hr, were below
detection. After 48 hr of the 1 µg/hr infusion, and then at 48 hr after the initiation of the 5
µg/hr infusion, the mean cisternal CSF concentrations of ziconotide were 2.3 ng/mL and
13.5 ng/mL, respectively. (See Figure 3.) Calculation of the LCSF: cisternal CSF: plasma
ratio using ziconotide concentrations measured concurrently in those spaces at 48 hr after
the infusion of 1 µg/hr, and then at 48 hr after 5 µg/hr, showed comparable values: 1: 0.017:
0.001 and 1: 0.015: 0.003, respectively (where 1 is taken as the concentration of ziconotide
in LCSF 48 hr after the initiation of 1 or 5 µg/hr infusions and all other values are expressed
as a ratio of that value). (See Table 4.)
Pharmacodynamics
General Behavior—After intrathecal bolus injection of ziconotide, 3 of the 5 dogs
exhibited whole body trembling. Panting was observed in 2 of the 5 dogs at approximately 1
hr post injection. All 5 dogs showed decreased arousal and activity but remained responsive
8 hr post injection. Dogs returned to normal baseline behavior 24 hr after injection. Almost
immediately following the intravenous bolus injection of ziconotide, 4 of the 5 dogs vomited
and 2 of the 5 had scleral vasodilation and facial erythema. At approximately 5 min post
injection, whole body trembling, laryngeal spasms, decreased muscle tone and slight
sedation were observed in 3 of the 5 dogs. All observed effects were absent 24 hr post
injection. At approximately 4–8 hr after initiation of 1 µg/hr continuous intrathecal infusion
of ziconotide, all 5 dogs exhibited whole body trembling, ataxia and decreased arousal and
activity levels. The observed whole body trembling and ataxia continued through the 1 µg/hr
48-hr infusion period. There was a tendency for this to increase in severity after the first 24
hr of the 5 µg/hr 48-hr infusion period, which immediately followed the first infusion period.
At 24 hr post termination of the intrathecal infusion, 3 of the 5 dogs had diarrhea and 1 had
hematuria.
Antinociception—Neither bolus intravenous nor intrathecal injection of ziconotide had an
effect upon skin twitch response (data not shown). During intrathecal infusion, all dogs
showed no significant anti-nociceptive behavior at 8 hr, but displayed a complete block of
the skin twitch response by 24 hr after initiation. Animals remained maximally blocked
through the remainder of the 1 µg/hr infusion and the subsequent 5 µg/hr infusion. (See
Figure 4).
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Temperature—At 24 hr after bolus intrathecal and intravenous ziconotide, body
temperature was not different from pretreatment baseline measurements (data not shown).
With continuous intrathecal infusion of 1 µg/hr, temperature increased modestly by
approximately 1.3°C and 1.7°C at 24 and 48 hr, respectively. With initiation of the 5 µg/hr
infusion, temperature displayed a continued additional rise of approximately 0.2°C and
0.8°C at 24 and 48 hr, respectively. All elevated temperatures returned to baseline values
24–72 hr after termination of the 5 µg/hr infusion. (See Figure 5.)
Blood Pressure and Heart Rate—Bolus intrathecal ziconotide (10 µg) was associated
with a modest decline in mean, diastolic, and systolic pressures and a mild tachycardia.
Bolus intravenous injection of ziconotide (0.1 mg/kg), however, resulted in a profound
(approximately 40 mmHg) and long lasting (>8 hours) fall in mean, diastolic, and systolic
pressures and this was accompanied by a corresponding tachycardia. (See Figure 6).
Continuous intrathecal infusion of 1 µg/hr had no effect upon blood pressure but did result in
tachycardia by 8–24 hours, peaking at around 24 hr. After initiation of the 5 µg/hr dose,
mean, diastolic, and systolic blood pressures showed a prominent reduction that persisted for
the remainder of the infusion. This was accompanied by a tachycardia and a general
reduction in heart rate to baseline levels by 72–96 hr. (See Figure 7.)
Respiratory Rate—After bolus intrathecal ziconotide (10 µg), 3 of the 5 dogs displayed
panting 20 min post injection, but respiratory rates remained otherwise unaffected through 6
hr. (Data not shown.) Bolus intravenous injection of ziconotide (0.1 mg/kg) resulted in a
moderate decrease in respiratory rates for approximately 3 hr post injection. This decrease in
respiratory rate corresponds with the observed slight sedation previously mentioned. (Data
not shown.) Continuous intrathecal infusion had no effect on respiratory rates. (Data not
shown.)
DISCUSSION
In the present study, we sought to characterize the spinal kinetics of ziconotide, a relatively
large hydrophilic peptide (25 amino acids; approximate molecular weight 2500 Da), in the
chronically spinal catheterized beagle dog.
Pharmacokinetic Model
The canine model has been widely employed in defining the physiological effects of a
variety of intrathecal antinociceptive agents, (26) including several opiates, (23, 24), alpha2
adrenergic agonists, (27, 28), neostigmine (22); NSAIDs (ketorolac) (29), and growth
factors (21) given as a bolus injection and/or infusion. The use of separate chronically
placed sampling and infusion catheters permits ongoing drug delivery and sampling without
contamination of the sampling route with the infusate. The use of the cisternal approach
reduces the likelihood of changes in local drug distribution due to local leakage at the dural
catheterization site. An important limitation of this and any sampling model is that removal
of the lumbar CSF (LCSF) serves to diminish the pool of available drug and likely causes an
overestimation of the rate of clearance. The impact of this intervention is reduced by
limiting the number and volume of samples. Importantly, given the effect of sampling, we
believe it is necessary to have concurrent comparisons with diffusion standards, such as
inulin, to permit the reliable determination of the pharmacokinetic behavior of the target
drug. The inert water-soluble agent, inulin, is widely used as a marker for the extravascular /
extracellular space. (See, for example (30) Its large size (approximately 5000 Da) reduces its
ability to diffuse though extracellular channels and its clearance from CSF is believed to
reflect the CSF clearance through rostral bulk flow and absorption in the arachnoid granules
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and subsequently into the venous drainage. (30,31,32) Agents cleared as inulin is are,
accordingly, believed to be primarily removed by a similar route.
Intrathecal injection
The lumbar CSF space is a poorly stirred volume with limited local fluid movement. (33,34,
35, 36) Accordingly, upon delivery into the intrathecal space, the injectate undergoes an
initial local redistribution that depends upon the volume and rate of delivery. Once
delivered, the injectate shows an initial fall in concentration that reflects: i) a progressive
dilution into the LCSF volume driven by oscillatory pressure waves. (34) A second
elimination phase is typically noted which reflects: i) ongoing local dilution in the CSF, ii)
movement into the adjacent spinal parenchyma, and iii) movement into and through the
adjacent meninges into the epidural space. (35,37). Such biphasic clearances have been
observed after bolus delivery in all drugs studies in this model (see below)
Previous work has shown that the principal variables governing the second phase of CSF
clearance of an intrathecally delivered agent are its physicochemical properties. Low
molecular weight, moderately lipid soluble molecules (e.g., alfentanil) show a rapid
movement from the lumbar CSF into tissue and through the meninges and into the
vasculature.(35). In contrast, larger, hydrophilic molecules such as ziconotide or inulin show
a more delayed clearance. (21) At the extreme, the clearance of a hydrophilic molecule that
diffuses poorly into tissue will display a half-life that approaches that of CSF. In the case of
the dog, this has been calculated to be on the order of approximately 2 hr. (32) While
systematic data are limited, it appears that hydrophilic molecules over several hundred Da
display increasingly similar clearance properties with increasing molecular weight. In the
present studies, ziconotide (approximately 2500 Da) displayed an elimination half-life after
bolus delivery on the order 3 hr. This is longer than the T1/2 calculated for smaller
hydrophilic molecules in this model (e.g. 0.9 hr for ketorolac (29); and 1.2 hr for morphine;
Allen and Yaksh, unpublished data). This clearance is slightly faster than that for inulin (3.9
h), and may some reflect binding in parenchyma and/or meninges. Interestingly, IT BDNF, a
large growth factor (27 KDa) showed a surprisingly rapid clearance from the CSF (0.7
hrs_(21). Such difference may reflect on other routes of clearance of free agent including
binding to meninges. In contrast, comparison of the initial distribution phase for ziconotide
and inulin (as well as the other hydrophilic molecules) indicates that they are essentially
identical, emphasizing that the initial dilution after bolus delivery represents a local dilution
in the CSF. Calculation of the ziconotide: inulin ratios, after bolus delivery, revealed that,
consistent with the comparable calculated half-lives, both molecules showed a similar acute
redistribution. On the other hand, consistent with the shorter T1/2ß, ziconotide LCSF
concentrations fell more rapidly than those of inulin, such that the ziconotide: inulin ratio
fell by a factor of approximately 3 and 12 at 3 hr and 8 hr, respectively. This difference in
the decline of lumbar ziconotide concentrations may reflect: i) a slightly more rapid
clearance of ziconotide into tissue, ii) adherence of the drug to local sites (i.e., specific and
non-specific binding), and/or iii) metabolism of ziconotide. Specific binding has been shown
for ziconotide in spinal tissues (11) and local absorption in the meninges is not unlikely.
Protein binding in CSF is not likely a factor, as protein concentrations are exceedingly low
compared to plasma. As regards metabolism, ziconotide is a peptide and can undergo
peptidic hydrolysis in the blood (38), though it appears relatively stable in in vivo studies.
(25)
Intravenous injection
Assessment of elimination after bolus IV delivery revealed a half life of 1.6 hrs, faster than
previously reported in rats and dogs after steady state infusion.(25) The elimination T1/2 of
ziconotide in CSF following IV injection was longer than that in plasma (1.64 hr vs 0.75 hr),
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but was comparable to the elimination T1/2 in CSF when ziconotide was given by IT bolus
(1.2 hr). This suggests that transfer of ziconotide out of the CSF is the rate-limiting for its
spinal action.
Intrathecal infusion
Dogs—Several observations emphasize the linearity of IT ziconotide pharmacokinetics. 1)
LCSF ziconotide concentrations remained stable upon reaching steady state between 8 and
48 hr of infusion of ziconotide at 1 and 5 µg/hr. 2) LCSF ziconotide concentrations at these
infusion doses corresponds to a ratio of approximately 1: 4, a value similar to the 5-fold
incremental dosing ratio. 3) Examination of the LCSF concentrations of ziconotide after
termination of intrathecal infusion revealed a T1/2 of 2.35 hr which is longer than the T1/2
calculated with bolus delivery (1.68 hr). This raises the likelihood that the longer T1/2
observed after continuous infusion reflect a clearance of ziconotide from spools such as the
tissue and meninges filled with continued exposure. Examination of plasma levels during
continuous infusion revealed a progressive rise relative to the LCSF concentration over the
48-hr interval, from 20,000: 1 at 8 hr to 600: 1 at 48 hr, reflecting the approach to time-
dependent equilibration of steady state CSF levels with plasma levels.
Based on the estimated ziconotide CL in CSF from bolus dosing (i.e., median value = 5.53
mL/h), and assuming linear PK, predicted steady-state CSF concentrations for a given IT
infusion regimen can be determined from the following equation:
Hence, for IT infusion rates of 1000 and 5000 ng/h, predicted CSF Css values would be 181
and 904 ng/mL, respectively. Measured lumbar CSF levels after these infusions were 419
and 2559, ng/mL respectively (Table 3). Similarly, predicted steady-state plasma Css values
for these IT infusion rates would be 0.09 and 0.43 ng/mL. Measured plasma levels after IT
infusion were found to be 0.11 and 1.26 pg.mL, respectively. (Table 3)
Cisternal CSF levels of ziconotide at steady state (with continuous infusion) in the dog are
proportional to the LCSF levels at steady state. The appearance of drug in the cisternal CSF
with lumbar delivery reflects i) movement from the site of injection to the cisterna by bulk
CSF redistribution and ii) movement from the site of injection to the blood and thence to the
brain. The concentrations in the cisternal CSF with LCSF delivery are determined by i) the
LCSF dose delivered, ii) the clearance of drug from the CSF, and iii) the effective dilution
volume of the spinal and cisternal CSF into which the injected drug is delivered. Drugs that
diffuse readily into tissue, or bind locally, will be accordingly cleared as they diffuse
rostrally. Hence, the cisternal: lumbar ratio of such a drug will, on average, be less than that
of a drug that does not diffuse into tissue and/or bind locally. Ziconotide LCSF: cisternal
ratios at steady state were on the order of 1: 0.02. Similar LCSF: cisternal ratios were
observed after IT delivery of a large growth factor (BDNF). (21) Importantly, the respective
ziconotide ratios were comparable when assessed after a low and high dose infusion (e.g.
0.011 at 1 µg/hr and 0.019 at 5 µg/hr) suggesting that rostral distribution is proportional to
the IT dose of ziconotide. The plasma concentrations measured concurrently are
approximately 0.1 times those observed in the cisterna. Given the poor blood-to-CSF
redistribution observed in the intravenous study, the presence of ziconotide in the cisternal
CSF is consistent with a rostral movement of the molecule from the lumbar intrathecal space
(as opposed to a spinal - vascular-cisternal route). A caveat to the above commentary is that
the concentrations of ziconotide in the cisternal CSF were assessed at a single time point, 48
hrs after the initiation of the infusion. While lumbar CSF concentrations appeared to be at
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steady state, at this time, we cannot be certain that there would not be higher levels of
cisternal ziconotide at longer intervals.
Human—These results compare favorably to a report on lumbar CSF PK in humans after
an acute (1 hr infusion) of ziconotide in humans. (16) In that work, after one-hour intrathecal
bolus administration of ziconotide in doses of 1 – 10 µg, an exponential clearance was noted
over 24 hr. Due to longer sampling intervals, the nature of the initial distribution could not
be estimated. However, a median LCSF half-life of 4.5 hr and a volume of distribution of 99
mL were calculated and the authors concluded that clearance of ziconotide in humans is due
to bulk redistribution of CSF. As in the dog, the pharmacokinetics of CSF ziconotide were
linear over the range of doses examined, based on the estimated T1/2 and Cmax values. As in
the canine model, the systemic bioavailability of the IT ziconotide was low, with plasma
concentrations in the human frequently being below the limit of detection of the ziconotide
assay. Several differences preclude an exact comparison of the human and dog data. First,
the Wermeling study employed a single catheter for delivery and sampling, so the sampling
did not begin until 1 hr after termination of infusion. Accordingly, it is not likely that the
drug had reached a steady state. Secondly, the use of a combined injection and sampling
system served to sample at the injection site. The dog model employed a sampling catheter
approximately 2 cm from the injection site. This allowed for an assessment of the local
distribution of injectate over a length of spinal cord considered important for influencing the
lumbar dermatomes. Accordingly, we were able to detect an initial distribution at the earliest
time point. Third, the use of a combined infusion–sampling catheter precluded an initial
sampling at injection. Indeed, in the human study, the first sample was not taken until 2 hrs
after the start of infusion and this would lead to an overestimation of time to clearance. In
spite of these differences, it is evident that both human and dog data indicate that intrathecal
ziconotide has linear kinetics and is cleared slowly.
Pharmacodynamics
Antinociception—Previous work has shown that the thermally evoked skin twitch is a
polysynaptic, small-afferent-evoked nociceptive reflex. (39) Other work in the dog has
shown this to be affected by opioids and alpha2 agonists given as a bolus. (24, 27) The
present study indicates that the bolus delivery of 10 µg of ziconotide had little effect upon
the skin twitch. In contrast, the continuous delivery of 1 ug/hr ziconotide produced a
maximal block of the skin twitch response by 24 hr that persisted throughout the 5 µg/hr
infusion period. These results are consistent with the results in acute thermal nociception in
rat models using both bolus injection and continuous infusion of intrathecal ziconotide. (8)
The reason for the difference in effect with bolus versus continuous infusion is not clear.
One possibility is that the large polycationic ziconotide molecule may diffuse into spinal
tissue relatively slowly along its concentration gradient. If the clearance of the drug from the
CSF is faster than the time required for the drug to penetrate to its molecular target within
the spinal parenchyma (i.e., the substantia gelatinosa), then the bolus delivery may not
permit the concentration gradient to persist long enough for effective concentrations of the
drug to be reached in the parenchyma. Using a microdialysis probe continuously infused
with radioiodinated ziconotide, Valentino, and colleagues (40) estimated the diffusion of the
peptide in rat brain parenchyma to be less than 1 mm in 2 hrs. This argument is consistent
with the observation that the onset of inhibition of the twitch response is delayed relative to
the time to steady state LCSF levels. It should be stressed that the skin twitch is a spinally
organized reflex and the present study does not define whether the local effects are related to
an alteration in the excitability of the reflex arc as well as an alteration in the ascending
sensory message. Nevertheless, the block of such a response in the absence of significant
changes in motor function (see below) argues against a general block of segmental motor
outflow.
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Behavioral Effects—Arousal, muscle tone, and coordination were not affected by
intrathecal bolus injection, but were transiently altered by chronic intrathecal infusion of
ziconotide. These results emphasize that the doses that were employed were without general
effect upon somatomotor function. The modest reduction in arousal after intravenous
delivery may reflect an effect secondary to the hypotension that was induced by this agent
given intravenously. A dose-related profile of side effects was noted in human studies after
spinal delivery. Thus, in humans, intrathecal ziconotide resulted in adverse effects, including
mild gait disturbance, nausea, dizziness, confusion, increased body temperature, and
somnolence. Modest hypotension has also been reported. (14, 15)
Physiological Effects—Ziconotide given intravenously resulted in hypotension. This
likely reflects the direct inhibition of the release of catecholamines from the peripheral
terminals by blockade of N-type calcium channels (40, 41) and is consistent with previous
reports. (42, 43, 44; 45). After continuous intrathecal infusion at 1 µg/hr, there was little
effect upon blood pressure, but at the 5 µg/hr dose, a fall in mean and diastolic pressures,
and a lesser fall in systolic pressure, were noted within several hours of altering the infusion
rate. Hypothetically, this sympatholytic effect may be mediated by a direct effect upon the
excitatory input into preganglionic sympathetic neurons. Spinal alpha2 adrenoceptor
agonists induce a direct inhibitory effect upon the excitability of spinal preganglionic
sympathetic neurons. (46) However, the 1.12 ng/mL ziconotide observed at steady state
(Table 3) is in the range of the IC50 for inhibition of sympathetic function by ziconotide.
Thus, we cannot completely exclude the likelihood that at least some component of this
effect is peripheral.
Clinical significance of intrathecal ziconotide kinetics
From the above reported observations and analyses, it can be concluded that intrathecally
delivered ziconotide is distributed in the lumbar and cisternal CSF as a large molecule in a
manner suggesting bulk redistribution in the spinal intrathecal space. The molecule displays
linear kinetics that are not altered by continuous infusion, coming to a steady state in LCSF
with continuous infusion within an 8-hr interval in this model -- a value consistent with the
half-life determined from clearance following bolus delivery or clearance from steady state.
Of particular interest in both the humans and dog study was the apparent delay in the onset
of the behavioral effects. In the dog study, skin twitch was not blocked at 8 hrs, although the
CSF steady state was apparently maximal at this time. In the human work, it was evident
that a lag time exists between the onset of analgesia in these pain patients and the LCSF-PK.
The source of this delay likely reflects upon the time required for the distribution from the
site of delivery and the spinal site of action. In the case of the N-type calcium channel
blocker this action lies within the superficial layer of the spinal dorsal horn. (5) Accordingly,
after IT delivery, the drug must reach the spinal levels mediating that pain state (e.g., lumbar
spinal cord, not roots). After bolus delivery, based on this dog study, this initial
redistribution may be relatively brief. However, with the use of infusion, it is likely that the
interval will be longer. At any given level, the agent must then penetrate to the site of spinal
action. While there are few systematic data, previous work has emphasized that the time to
onset of inhibition of dorsal horn neurons firing correlates with the time of onset of
analgesia. Agents that are lipid soluble will penetrate rapidly and show a correspondingly
more rapid onset than that observed with polar molecules. (47, 48) Moreover, consistent
with spinal cord size, the time of onset of effect after a particular IT drug such as morphine
is shortest in small species (e.g., mouse) and longest in larger species (e.g., dog and human).
Accordingly, it is not surprising that there is a definable hysteresis between LCSF steady
state and onset of action of large, relatively poorly diffusible molecules such as ziconotide.
These comments reflect upon the likely need to increment the dosing of intrathecal
ziconotide to achieve optimal dosing. Based on CSF levels in the dog we would estimate
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that CSF steady state will require around 8 hrs. One would then consider that time to diffuse
into tissue would require an additional interval. It is not possible from these studies to
estimate the additional interval, but given the time to analgesia observed in the dog infusion
studies, this interval would occur inside of 24 hrs. From a clinical perspective, dose
incrementation should therefore not occur at intervals of less than 24 hrs. As non-spinal side
effects increase as a function of dose, rapid incrementation would tend to overshoot the
minimum therapeutic levels and increase the likelihood of untoward effects. In humans,
confusion and other mental changes, as well as autonomic effects, have been reported to
occur at roughly 24–48 hr (20, 49) or 48–72 hr (15) intervals after incrementation of
intrathecal ziconotide and probably reflect a supraspinal action. The present studies indicate
that increasing plasma versus LCSF levels continue to rise through 48 hr. Though systemic
ziconotide displays limited systemic bioavailability, the delayed onset of side effects may
reflect a role for systemic redistribution. We did not examine cisternal ziconotide
concentrations at shorter time intervals than 48 hrs, but it seems likely that supraspinal
steady state levels will occur after the LCSF Cmax levels that were observed between 8 and
24 hr. Importantly, the stability and linearity of the kinetics after either bolus or continuous
infusion observed in these studies provides assurance that drug effects may be predictably
titrated by slower incrementation than used in initial clinical studies of ziconotide. (15, 20,
17, 50)
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The concentrations of ziconotide (ng/mL) and inulin (DPM/mL) in the lumbar CSF (top) as
a function of time after the bolus intrathecal injection of ziconotide (10µg) and inulin (1µCi)
in 1 mL. The bottom panel presents the ratio of ziconotide to inulin as a function of time
after intrathecal delivery. Each point represents the mean and SEM of data from 5 dogs.
Calculated kinetics are presented in Table 1.
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The concentrations of ziconotide (ng/mL) in the plasma and lumbar CSF, and the ratio of
CSF: plasma levels after the bolus intravenous delivery of ziconotide (0.1 mg/kg). Results
presented represent the mean and SEM of data from 5 dogs. Calculated kinetics are
presented in Table 2.
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The concentrations of ziconotide (ng/ml) in the plasma, lumbar CSF, and the cisternal CSF,
and the ratio of CSF: plasma levels at intervals before, during, and after continuous infusion
of ziconotide. From 0 to 48 hr, ziconotide was infused at 1µg/hr. From 48 to 96 hr
ziconotide was delivered at the rate of 5µg/hr. Cisternal CSF was sampled immediately prior
to the initiation of infusion just before changing the infusion rate to 5 µg/hr and just before
terminating the infusion of 5µg/hr. Results presented represent the mean and SEM of data
from 5 dogs. Calculated kinetics for the two infusion rates and for the clearance of
ziconotide after termination of 5 µg/hr infusion in Table 3.
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The skin twitch response latency during the continuous intrathecal infusion of ziconotide.
From 0 to 48 hr, ziconotide was infused at 1 µg/hr. From 48 to 96 hr, ziconotide was
delivered at the rate of 5 µg/hr. Results presented represent the mean and SEM of data from
5 dogs.
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The rectal temperature assessed during the continuous intrathecal infusion of ziconotide.
From 0 to 48 hr, ziconotide was infused at 1µg/hr. From 48 to 96 hr, ziconotide was
delivered at the rate of 5µg/hr. Results presented represent the mean and SEM of data from 5
dogs.
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The blood pressure and heart rate responses observed after the intravenous delivery of a
bolus of ziconotide (0.1 mg/kg) at t = 0. Results presented represent the mean and SEM of
data from 5 dogs.
Yaksh et al. Page 22











The blood pressure and heart rate responses observed during the continuous intrathecal
infusion of ziconotide. From 0 to 48 hr, ziconotide was infused at 1 µg/hr. From 48 to 96 hr,
ziconotide was delivered at the rate of 5 µg/hr. Results presented represent the mean and
SEM of data from 5 dogs.
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Table 1






N 4 4 5
C0 (ng/mL or
dpm/mL) Median NA 8781 1348776




Median 0.52 6698 1189820
Range 0.3 1– 0.72 5470 – 6840 649480 – 1566460
Tmax
(h) Median 0.25 0.06 0.08
Range 0.25 – 0.75 0.03 – 0.08 0.03 – 0.08
T½-α (hrs)
Median 0.61 0.14 0.14
Range 0.2–2.1 0.06–0.23 0.06–0.32
T½-β (h)
Median 1.25 1.68 3.04




Median 0.85 1879 487562
Range 0.61 – 3.91 1488 – 2936 258576 – 593643
CLa or CL/Fb
(mL/h) Median 11740b 5.53a 4.66a




Range 12932 – 33328b 8.5 – 20.8a 6.4 – 65.0a
Vss
(mL) Median NA 1.32 2.34
Range NA 0.96 – 1.66 0.69 – 8.49
Note 1: C0 = initial concentration (back-extrapolated to dose time; NA = not applicable.
Note 2: Vss is much smaller than Vz, indicating that appreciable elimination of drug occurs before distribution equilibrium is achiePved.
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Table 2

















Range 0.03 – 0.08 0.
T½-β (h) Median 1. 1.








Range 3027 – 8613a 22184 – 91574b








Range 1979 – 7840 N
NA = not applicable.
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Table 4
Ratio of Lumbar:Cisternal:Plasma Ziconotide Concentrations Measured Concurrently at 48 Hours After
Intrathecal Infusion of 1µg and 5µg Ziconotide
Lumbar Cisternal Plasma
Mean ± SEM Mean ± SEM Mean ± SEM
Post 1µg/hr 1 ± 0 0.0171 ± 0.0114 0.0007 ± 0.0004
Post 5µg/hr 1 ± 0 0.0153 ± 0.0082 0.0026 ± 0.0021
Neuromodulation. Author manuscript; available in PMC 2013 November 01.
